Class: Antiplatelet Agent
Dosage Forms. Tablet: 5 mg, 10 mg
Common FDA Label Indication, Dosing, and Titration.
1. Prevention of thromboembolism after percutaneous coronary intervention: 60 mg po once, then 10 mg po daily with aspirin, 75-325 mg po daily
1. Prevention of thromboembolism in acute coronary syndrome: 30 mg po once, then 10 mg po daily with aspirin, 100 mg or less po daily
MOA. Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets.
Drug Characteristics: Prasugrel
Medication Safety Issues: Prasugrel
Drug Interactions: Prasugrel
Adverse Reactions: Prasugrel
Efficacy Monitoring Parameters. Prevention of clotting. The aPTT assay can be used as a qualitative indicator of anticoagulation status.
Toxicity Monitoring Parameters. Monitor for signs and symptoms of bleeding. Monitor BP, HR.
Key Patient Counseling Points. May be given with or without food. Tablet may be crushed, but should not be split for purposes of dividing doses.
Clinical Pearls. After percutaneous coronary intervention, dosing should continue for 12 mo if stent is placed, and at least 15 mo if drug-eluting stent is placed. In patients weighing <60 kg, may consider dose of 5 mg po daily.